The GLP-1 Collective is now a certified nonprofit, working to make GLP-1 medications affordable and accessible. With nearly 20,000 signatures, support groups, educational tools, and more, we’re building a stronger community and fighting for lasting solutions.

The FDA has removed Tirzepatide from the drug shortage list, setting a timeline that will limit access to compounded versions by February 2025. This decision could lead to similar restrictions on Semaglutide and underscores the urgent need for permanent, affordable solutions for GLP-1 medications.

Compounding pharmacies have provided critical access, but lasting options like FDA-approved generics, lower prices, or mandatory insurance coverage are essential to ensure patients can manage chronic conditions without barriers. This update highlights the growing urgency to secure accessible, affordable treatments for all.

One month into our fight for affordable GLP-1 medications, we’ve achieved over 14,000 signatures, raised $1,000, secured three media interviews, and shared dozens of powerful stories. Today, we took another step by contacting the FDA ahead of their decision on Tirzepatide, which could drastically impact access.

This fight is about lasting solutions—affordable access to Tirzepatide, Semaglutide also known as Wegovy, Mounjaro, Zepbound, and Ozempic. Join the movement, share the petition, and help us push for real change. Together, we’re making an impact!

In just three weeks, our petition for affordable GLP-1 medications has reached nearly 12,000 signatures and has been featured in two media articles, with more coverage on the way.

Let’s make this final week count—share the petition and help create real change!

Our petition for affordable GLP-1 medications was featured in USA Today. With just eight days left, every signature and share helps us push for better access to these life-changing treatments. Join the movement and make a difference!

Update on the fight for affordable access to GLP-1 medications, highlighting recent milestones, including a feature in Politico, USA Today, and a call for support to amplify the message before the upcoming deadline.

The FDA’s decision has been delayed until December 11, 2024, giving us a crucial window to build support. In just three days, over 6,500 signatures have been gathered.

Efforts are focused on raising awareness, engaging influencers, and amplifying personal stories to show the real impact of these medications. Support the movement by signing, donating, or sharing your story to push for affordable, lasting solutions.

This fight is about more than medications—it's about people’s health, dignity, and hope for a better future. Learn how the GLP-1 Collective is pushing back against Big Pharma, advocating for lasting solutions, and amplifying the voices of those whose lives have been transformed.

First Update: The Fight for Affordable GLP-1 Access

The FDA has delayed its decision to December 11, 2024. With just under a month to act, the GLP-1 Collective is gaining momentum, adding 500+ signatures in two days. This update outlines how you can help—through sharing, donating, telling your story, and engaging the media.

Together, we can fight for affordable GLP-1 medications and ensure the FDA hears our voices.